Virtual Medical Academy

Atopic Dermatitis in Elderly Patients: Discussing the Safety of Lebrikizumab in an 86-Year-Old Patient.

VMA English

Overview

In this video, Dr. Naiem T. Issa reviews the established safety profile of Ebglyss®
(lebrikizumab), including key safety considerations, common adverse events, and its use
without routine lab monitoring or dose adjustments. He also presents a real-world case of
an 86-year-old patient with severe atopic dermatitis, demonstrating rapid improvements in
BSA and itch severity within just 2 weeks of treatment, highlighting the safety and fast
efficacy of lebrikizumab in elderly patients.

This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

● Review the established safety profile of lebrikizumab in adults and adolescents.
● Highlight key safety considerations, including no routine lab monitoring and no dose adjustments by age or weight.
● Summarize common adverse events reported in clinical trials.
● Demonstrate the rapid efficacy and safety of lebrikizumab through a real-world case in an elderly patient with comorbidities.

Upgrade Your Plan
  • clock Last Update 08/2026
  • adjust VMA